Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Stephens. They set an "overweight" rating and a $140.00 price target on the stock.
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update [Yahoo! Finance]
Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at Leerink Partnrs from an "underperform" rating to a "market perform" rating.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $121.00 to $168.00. They now have a "buy" rating on the stock.